Experience

Davis Polk advised the underwriters in connection with the $72.5 million U.S. initial public offering of 5,175,000 common shares of Cynapsus Therapeutics Inc., including 675,000 common…

Davis Polk advised Biotie Therapies Corp. (“Biotie”) on its $56.7 million U.S. initial public offering of 3,806,047 American Depositary Shares (“ADSs”) representing 304,483,760 ordinary…

Davis Polk is advising Bio-Reference Laboratories, Inc. in connection with its approximately $1.47 billion acquisition by OPKO Health, Inc. Under the terms of the agreement, holders of Bio…